75.00Open75.00Pre Close0 Volume5 Open Interest270.00Strike Price0.00Turnover53.12%IV15.45%PremiumMay 16, 2025Expiry Date28.83Intrinsic Value100Multiplier9DDays to Expiry46.17Extrinsic Value100Contract SizeAmericanOptions Type0.8983Delta0.0071Gamma9.85Leverage Ratio-0.2697Theta0.0585Rho8.84Eff Leverage0.0833Vega
Madrigal Pharmaceuticals Stock Discussion
Can Madrigal's Rezdiffra Breakthrough in Cirrhosis Patients Transform Liver Disease Treatment?
📊⚡️📊
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$